To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca

PHASE2CompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Keratoconjunctivitis Sicca
Interventions
DRUG

R348 Ophthalmic Solution, 0.2%

R348 Ophthalmic Solution, 0.2% 1 drop per eye twice a day for 12 weeks.

DRUG

R348 Ophthalmic Solution, 0.5%

R348 Ophthalmic Solution, 0.5% 1 drop per eye twice a day for 12 weeks.

DRUG

Placebo

Placebo Ophthalmic Solution 1 drop per eye twice a day for 12 weeks.

Trial Locations (20)

27262

Cornerstone Eyecare, High Point

28204

Mundorf Eye Center, Charlotte

28210

Charlotte Eye Ear Nose and Throat Associates, PA, Charlotte

29464

Glaucoma Consultants and Center for Eye Research, Mt. Pleasant

30076

Coastal Research Associates, Roswell

30260

Clayton Eye Center, Morrow

33603

International Research Center, Brandon

34994

East Florida Eye Institute, Stuart

37411

Chattanooga Eye Institute, Chattanooga

40033

Koffler Vision Group, Lebanon

40217

Taustine Eye Center, Louisville

44115

Abrams Eye Center, Cleveland

60169

Chicago Cornea Consultants, Hoffman Estates

60634

Chicago Research Center, Chicago

63090

Comprehensive Eye Care, Ltd/Vision Research Institute, LLC, Washington

78209

Eye Clinics of South Texas, San Antonio

90701

Sall Research Medical Center, Artesia

94954

North Bay Eye, Petaluma

95670

Martel Medical Eye Group, Rancho Cardova

808134

Specialty Eye Care, Parker

Sponsors
All Listed Sponsors
lead

Rigel Pharmaceuticals

INDUSTRY